Citations

Showing 10 of 108152 citations.

Core Genome Multilocus Sequence Typing and Prediction of Antimicrobial Susceptibility Using Whole-Genome Sequences of Escherichia coli Bloodstream Infection Isolates
Banerjee, Ritu , Beisken, Stephan , Posch, Andreas E. , Johnston, Brian , Johnson, James R. , Patel, Robin , Patel, Robin , Cunningham, Scott A.

Mayo Clinic

Antimicrobial Agents and Chemotherapy | August 23, 2021 | Volume: 65 | Issue: 11 | Pages: No page available

10.1128/aac.01139-21 | PMID 34424049 Get It

In total, 50 Escherichia coli bloodstream isolates from the clinical laboratory and 12 E. coli isolates referred for pulsed-field gel electrophoresis (PFGE) were sequenced, assessed for clonality using core genome multilocus sequence typing (cgMLST), and evaluated for genomic susceptibility predictions using ARESdb. Results of sequence typing using whole-genome sequencing (WGS)-based MLST and sequence type (ST)-specific PCR were identical.
Recommended protocols for the Multiple Sleep Latency Test and Maintenance of Wakefulness Test in adults: guidance from the American Academy of Sleep Medicine
Krahn, Lois E., Arand, Donna L., Avidan, Alon Y. , Davila, David, Ruoff, Chad , Harrod, Christopher G., Ruoff, Chad M., Ruoff, Chad M , Avidan, Alon Y , DeBassio, William A.

Mayo Clinic

Journal of Clinical Sleep Medicine | August 23, 2021 | Volume: 17 | Issue: 12 | Pages: 2489-2498

10.5664/jcsm.9620 | PMID 34423768 Get It

Age defining immune effector cell associated neurotoxicity syndromes in aggressive large B cell lymphoma patients treated with axicabtagene ciloleucel
Wudhikarn, Kitsada , Bansal, Radhika , Khurana, Arushi , Hathcock, Matthew , Braksick, Sherri A. , Wang, Yucai , Johnston, Patrick B. , Ansell, Stephen M. , Lin, Yi , Paludo, Jonas , Wang, Yucai , Ansell, Stephen M , Lin, Yi , Bennani, N. Nora , Paludo, Jonas , Villasboas, José C.

Mayo Clinic

American Journal of Hematology | August 23, 2021 | Volume: 96 | Issue: 11 | Pages: No page available

10.1002/ajh.26330 | PMID 34424554 Get It

Gigantic retroperitoneal metastatic seminoma encasing the aorta in a young man
Wahab, Abdul, Hayat, Muhammad Hashim , Yousaf, Amman , Tariq, Raseen , Tariq, Raseen

Mayo Clinic

BMJ Case Reports | August 23, 2021 | Volume: 14 | Issue: 8 | Pages: e243190

10.1136/bcr-2021-243190 | PMID 34426421 Get It

Genome-Wide miRNA Expression Profiling of Molecular Subgroups of Peripheral T-cell Lymphoma
Lone, Waseem , Bouska, Alyssa , Sharma, Sunandini , Amador, Catalina, Herek, Tyler A. , Heavican, Tayla B., Yu, Jiayu , Lim, Soon Thye , Ong, Choon Kiat , Slack, Graham W. , Savage, Kerry J. , Rosenwald, Andreas , Ott, German , Cook, James R. , Greiner, Timothy C. , Weisenburger, Dennis D. , Motta, Giovanna , Chan, Wing C. , Iqbal, Javeed , Saumyaranjan, Mallick , Ong, Choon Kiat , Feldman, Andrew L , Weisenburger, Dennis D , Melle, Federica , Savage, Kerry J , Bouska, Alyssa , Iqbal, Javeed , Lone, Waseem G , Feldman, Andrew L. , Rimsza, Lisa M. , McKeithan, Timothy W. , Pileri, Stefano , Vose, Julie M.

Mayo Clinic

Clinical Cancer Research | August 23, 2021 | Volume: 27 | Issue: 21 | Pages: 6039-6053

10.1158/1078-0432.ccr-21-0573 | PMID 34426436 Get It

Abstract Purpose: Peripheral T-cell lymphoma (PTCL) is a heterogeneous group of non–Hodgkin lymphomas with aggressive clinical behavior. We performed comprehensive miRNA profiling in PTCLs and corresponding normal CD4+ Th1/2 and TFH-like polarized subsets to elucidate the role of miRNAs in T-cell lymphomagenesis. Experimental Design: We used nCounter (NanoString Inc) for miRNA profiling and validated using Taqman qRT-PCR (Applied Biosystems, Inc). Normal CD4+ T cells were polarized into effector Th subsets using signature cytokines, and miRNA significance was revealed using functional experiments. Results: Effector Th subsets showed distinct miRNA expression with corresponding transcription factor expression (e.g., BCL6/miR-19b, -106, -30d, -26b, in IL21-polarized; GATA3/miR-155, miR-337 in Th2-polarized; and TBX21/miR-181a, -331-3p in Th1-polarized cells). Integration of miRNA signatures suggested activation of TCR and PI3K signaling in IL21-polarized cells, ERK signaling in Th1-polarized cells, and AKT–mTOR signaling in Th2-polarized cells, validated at protein level. In neoplastic counterparts, distinctive miRNAs were identified and confirmed in an independent cohort. Integrative miRNA–mRNA analysis identified a decrease in target transcript abundance leading to deregulation of sphingolipid and Wnt signaling and epigenetic dysregulation in angioimmunoblastic T-cell lymphoma (AITL), while ERK, MAPK, and cell cycle were identified in PTCL subsets, and decreased target transcript abundance was validated in an independent cohort. Elevated expression of miRNAs (miR-126-3p, miR-145-5p) in AITL was associated with poor clinical outcome. In silico and experimental validation suggest two targets (miR-126→ SIPR2 and miR-145 → ROCK1) resulting in reduced RhoA-GTPase activity and T–B-cell interaction. Conclusions: Unique miRNAs and deregulated oncogenic pathways are associated with PTCL subtypes. Upregulated miRNA-126-3p and miR-145-5p expression regulate RhoA-GTPase and inhibit T-cell migration, crucial for AITL pathobiology.
Results of a randomized phase 3 study of oral sapacitabine in elderly patients with newly diagnosed acute myeloid leukemia (SEAMLESS)
Kantarjian, Hagop M. , Begna, Kebede H. , Altman, Jessica K. , Goldberg, Stuart L. , Strickland, Stephen A. , Arellano, Martha , Claxton, David F. , Baer, Maria R. , Gautier, Marc, Berman, Ellin , Seiter, Karen , Solomon, Scott R. , Schiller, Gary J. , Luger, Selina M. , Butrym, Aleksandra , Gaïdano, Gianluca , Thomas, Xavier , Montesinos, Pau , Rizzieri, David A. , Quick, Donald P., Gaur, Rakesh , Maness, Lori J., Kadia, Tapan M. , Chiao, Judy H. , Sekeres, Mikkael A , Strickland, Stephen Anthony , Arellano, Martha L , Claxton, David F , Baer, Maria R , Berman, Ellin , Seiter, Karen , Solomon, Scott R , Schiller, Gary J , Luger, Selina M , Butrym, Aleksandra , Gaidano, Gianluca , Thomas, Xavier G , Montesinos, Pau , Rizzieri, David A , Venugopal, Parameswaran , Gaur, Rakesh , Kadia, Tapan M , Ravandi, Farhad , Buyse, Marc E , Chiao, Judy H , Kantarjian, Hagop , Goldberg, Stuart L. , Sekeres, Mikkael A. , Buyse, Marc

Mayo Clinic

Cancer | August 23, 2021 | Volume: 127 | Issue: 23 | Pages: 4421-4431

10.1002/cncr.33828 | PMID 34424530 Get It

BackgroundAcute myeloid leukemia (AML) is fatal in elderly patients who are unfit for standard induction chemotherapy. The objective of this study was to evaluate the survival benefit of administering sapacitabine, an oral nucleoside analogue, in alternating cycles with decitabine, a low‐intensity therapy, to elderly patients with newly diagnosed AML.MethodsThis randomized, open‐label, phase 3 study (SEAMLESS) was conducted at 87 sites in 11 countries. Patients aged ≥70 years who were not candidates for or chose not to receive standard induction chemotherapy were randomized 1:1 to arm A (decitabine in alternating cycles with sapacitabine) received 1‐hour intravenous infusions of decitabine 20 mg/m2 once daily for 5 consecutive days every 8 weeks (first cycle and subsequent odd cycles) and sapacitabine 300 mg twice daily on 3 consecutive days per week for 2 weeks every 8 weeks (second cycle and subsequent even cycles) or to control arm C who received 1‐hour infusions of decitabine 20 mg/m2 once daily for 5 consecutive days every 4 weeks. Prior hypomethylating agent therapy for preexisting myelodysplastic syndromes or myeloproliferative neoplasms was an exclusion criterion. Randomization was stratified by antecedent myelodysplastic syndromes or myeloproliferative neoplasms, white blood cell count (<10 × 109/L and ≥10 × 109/L), and bone marrow blast percentage (≥50% vs <50%). The primary end point was overall survival (OS). Secondary end points were the rates of complete remission (CR), CR with incomplete platelet count recovery, partial remission, hematologic improvement, and stable disease along with the corresponding durations, transfusion requirements, number of hospitalized days, and 1‐year survival. The trial is registered at ClinicalTrials.gov (NCT01303796).ResultsBetween October 2011 and December 2014, 482 patients were enrolled and randomized to receive decitabine administered in alternating cycles with sapacitabine (study arm, n = 241) or decitabine monotherapy (control arm, n = 241). The median OS was 5.9 months on the study arm versus 5.7 months on the control arm (P = .8902). The CR rate was 16.6% on the study arm and 10.8% on the control arm (P = .1468). In patients with white blood cell counts <10 × 109/L (n = 321), the median OS was higher on the study arm versus the control arm (8.0 vs 5.8 months; P = .145), as was the CR rate (21.5% vs 8.6%; P = .0017).ConclusionsThe regimen of decitabine administered in alternating cycles with sapacitabine was active but did not significantly improve OS compared with decitabine monotherapy. Subgroup analyses suggest that patients with baseline white blood cell counts <10 × 109/L might benefit from decitabine alternating with sapacitabine, with an improved CR rate and the convenience of an oral drug. These findings should be prospectively confirmed.
Airway Exposure to Polyethyleneimine Nanoparticles Induces Type 2 Immunity by a Mechanism Involving Oxidative Stress and ATP Release
Srisomboon, Yotesawee, Ohkura, Noriyuki , Iijima, Koji, Maniak, Peter J., Kita, Hirohito , O’Grady, Scott M. , Kita, H , Kobayashi, Takao

Mayo Clinic

International Journal of Molecular Sciences | August 23, 2021 | Volume: 22 | Issue: 16 | Pages: 9071

10.3390/ijms22169071 | PMID 34445774 Get It

Polyethyleneimine (PEI) induced immune responses were investigated in human bronchial epithelial (hBE) cells and mice. PEI rapidly induced ATP release from hBE cells and pretreatment with glutathione (GSH) blocked the response. PEI activated two conductive pathways, VDAC-1 and pannexin 1, which completely accounted for ATP efflux across the plasma membrane. Moreover, PEI increased intracellular Ca2+ concentration ([Ca2+]i), which was reduced by the pannexin 1 inhibitor, 10Panx (50 μM), the VDAC-1 inhibitor, DIDS (100 μM), and was nearly abolished by pretreatment with GSH (5 mM). The increase in [Ca2+]i involved Ca2+ uptake through two pathways, one blocked by oxidized ATP (oATP, 300 μM) and another that was blocked by the TRPV-1 antagonist A784168 (100 nM). PEI stimulation also increased IL-33 mRNA expression and protein secretion. In vivo experiments showed that acute (4.5 h) PEI exposure stimulated secretion of Th2 cytokines (IL-5 and IL-13) into bronchoalveolar lavage (BAL) fluid. Conjugation of PEI with ovalbumin also induced eosinophil recruitment and secretion of IL-5 and IL-13 into BAL fluid, which was inhibited in IL-33 receptor (ST2) deficient mice. In conclusion, PEI-induced oxidative stress stimulated type 2 immune responses by activating ATP-dependent Ca2+ uptake leading to IL-33 secretion, similar to allergens derived from Alternaria.
Quantitative Tyrosine Phosphoproteome Profiling of AXL Receptor Tyrosine Kinase Signaling Network
Wu, Xinyan , Wang, Li , Pearson, Nicole A, Renuse, Santosh , Cheng, Ran , Madugundu, Anil K. , Xu, Yaoyu, Gill, Parkash S. , Pandey, Akhilesh , Pandey, Akhilesh , Pandey, Akhilesh , Liang, Ye , Mun, Dong‐Gi

Mayo Clinic

Cancers | August 23, 2021 | Volume: 13 | Issue: 16 | Pages: 4234

10.3390/cancers13164234 | PMID 34439388 Get It

Overexpression and amplification of AXL receptor tyrosine kinase (RTK) has been found in several hematologic and solid malignancies. Activation of AXL can enhance tumor-promoting processes such as cancer cell proliferation, migration, invasion and survival. Despite the important role of AXL in cancer development, a deep and quantitative mapping of its temporal dynamic signaling transduction has not yet been reported. Here, we used a TMT labeling-based quantitative proteomics approach to characterize the temporal dynamics of the phosphotyrosine proteome induced by AXL activation. We identified >1100 phosphotyrosine sites and observed a widespread upregulation of tyrosine phosphorylation induced by GAS6 stimulation. We also detected several tyrosine sites whose phosphorylation levels were reduced upon AXL activation. Gene set enrichment-based pathway analysis indicated the activation of several cancer-promoting and cell migration/invasion-related signaling pathways, including RAS, EGFR, focal adhesion, VEGFR and cytoskeletal rearrangement pathways. We also observed a rapid induction of phosphorylation of protein tyrosine phosphatases, including PTPN11 and PTPRA, upon GAS6 stimulation. The novel molecules downstream of AXL identified in this study along with the detailed global quantitative map elucidating the temporal dynamics of AXL activation should not only help understand the oncogenic role of AXL, but also aid in developing therapeutic options to effectively target AXL.
Clinical and molecular predictors of fibrotic progression in essential thrombocythemia: A multicenter study involving 1607 patients
Loscocco, Giuseppe Gaetano , Guglielmelli, Paola , Gangat, Naseema , Rossi, Elena, Mannarelli, Carmela, Betti, Silvia, Maccari, Chiara , Ramundo, Francesco , Jadoon, Yamna, Gesullo, Francesca, Ceglie, Sara , Pardanani, Animesh , Tefferi, Ayalew , Loscocco, Giuseppe Gaetano , Pardanani, Animesh , De Stefano, Valerio , Tefferi, Ayalew , Vannucchi, Alessandro M , Guglielmelli, Paola , Betti, Silvia, Paoli, Chiara, Stefano, Valerio De , Vannucchi, Alessandro M.

Mayo Clinic

American Journal of Hematology | August 23, 2021 | Volume: 96 | Issue: 11 | Pages: 1472-1480

10.1002/ajh.26332 | PMID 34424575 Get It

Abstract The current retrospective study involving a total of 1607 patients was designed to identify clinical and molecular variables that were predictive of inferior myelofibrosis‐free survival (MFS) in WHO‐defined essential thrombocythemia (ET), utilizing three independent patient cohorts: University of Florence, Italy ( n = 718); Mayo Clinic, USA ( n = 479) and Policlinico Gemelli, Catholic University, Rome, Italy ( n = 410). The Florence patient cohort was first examined to identify independent risk factors for MFS, which included age > 60 years (HR 2.5, 95% CI 1.3–4.9), male sex (2.1, 1.2–3.9), palpable splenomegaly (2.1, 1.2–3.9), CALR 1/1‐like or MPL mutation (3.4, 1.9–6.1) and JAK2 V617F variant allele frequency > 35% (4.2, 1.6–10.8). Subsequently, an operational molecular risk category was developed and validated in the other two cohorts from Mayo Clinic and Rome: “high molecular risk” category included patients with JAK2 V617F VAF >35%, CALR type 1/1‐like or MPL mutations; all other driver mutation profiles were assigned to “low molecular risk” category. The former, compared to the latter molecular risk category, displayed significantly higher risk of fibrotic transformation: Florence cohort with respective fibrotic transformation risk rates of 8% vs. 1.2% at 10 years and 33% vs. 8% at 20 years ( p < 0.001; HR 6.1; 95% CI 3.2–11.7); Mayo Cohort, 16% vs. 7% at 10 years and 44% vs. 25% at 20 years ( p < 0.001; HR 2.5; 95% CI 1.6–4.1); and Rome cohort 7.8% vs. 4.6% at 10 years and 31.2% vs. 7.1% at 20 years ( p = 0.007, HR 2.7; 95% CI 1.3–5.8). The present study provides practically useful risk signals for fibrotic transformation in ET and facilitates identification of patients who require close monitoring and appropriate counseling.
003 Autoimmune encephalitis antibody biomarkers: frequency, age and sex associations
Lennon, Vanda A. , Ζεκερίδου, Αναστασία , Kunchok, Amy , Klein, Christopher J. , Flanagan, Eoin P. , Dubey, Divyanshu , McKeon, Andrew , Pittock, Sean J.

Mayo Clinic

Oral abstracts | August 23, 2021 | Volume: No volume available | Issue: No issue available | Pages: A1.3-A2

10.1136/bmjno-2021-anzan.3 Get It